BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 17912176)

  • 1. [Endometrial ablation versus hysterectomy in women treated with tamoxifen].
    Capuano I; Caporale A; Vagnetti P; Di Domenico A; Felicetti M; Torella M; Borrelli AL
    Minerva Ginecol; 2007 Oct; 59(5):499-504. PubMed ID: 17912176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
    Hauth E; Libera H; Kimmig R; Forsting M
    Rofo; 2006 Mar; 178(3):316-23. PubMed ID: 16508840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of the endometrial pathology using flexible ambulatory hysteroscopy of patients treated with Tamoxifen].
    Kuzmanov B
    Akush Ginekol (Sofiia); 2004; 43(3):32-3. PubMed ID: 15341254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Zhu Y; Yang J
    J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hysteroscopic and nonhysteroscopic endometrial ablation.
    Vilos GA
    Obstet Gynecol Clin North Am; 2004 Sep; 31(3):687-704, xi. PubMed ID: 15450328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
    Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
    Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
    Kesim MD; Aydin Y; Atis A; Mandiraci G
    Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy.
    Bourdrez P; Bongers MY; Mol BW
    Fertil Steril; 2004 Jul; 82(1):160-6, quiz 265. PubMed ID: 15237006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding.
    Fotiou S; Tserkezoglou A; Hadjieleftheriou G; Apostolikas N; Karydas I; Stravolemos K
    Anticancer Res; 1998; 18(1B):625-9. PubMed ID: 9584044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathology of the endometrium in breast cancer patients treated with tamoxifen (nolvadex)].
    Ivanova V; Karaivanov M; Marinov E; Gorchev G; Velkova A; Khristova P
    Akush Ginekol (Sofiia); 2003; 42(5):3-8. PubMed ID: 14682005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tamoxifen, endometrial cancer risk and liquid based cytology. A paradigmatic case].
    Fambrini M; Buccoliero AM; Pieralli A; Andersson KL; Mattei A; Scarselli G; Taddei G; Marchionni M
    Minerva Ginecol; 2011 Oct; 63(5):465-70. PubMed ID: 21926955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial ablation versus hysterectomy: STOP-DUB.
    Weber AM; Munro MG
    Medscape Womens Health; 1998 May; 3(3):3. PubMed ID: 9732095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial ablation--long-term complications.
    Sinha P
    Wiad Lek; 2004; 57 Suppl 1():276-7. PubMed ID: 15884256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers.
    Gibson LE; Barakat RR; Venkatraman ES; Hoskins WJ
    Cancer J Sci Am; 1996; 2(1):35-8. PubMed ID: 9166496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
    Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
    BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of tamoxifen of endometrium].
    Bai P; Sun J; Zhang K
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):226-8. PubMed ID: 11783367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen.
    Marconi D; Exacoustos C; Cangi B; Perroni A; Zupi E; Valli E; Romanini C
    J Am Assoc Gynecol Laparosc; 1997 May; 4(3):331-9. PubMed ID: 9154782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR;
    Hum Reprod; 2005 Jan; 20(1):294-301. PubMed ID: 15513977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.